Skip to main content

Branded

  • Oramed calls oral insulin drug trial 'successful'

    JERUSALEM Oramed Pharmaceuticals has seen promising results from a clinical trial of an oral insulin for diabetes, the Israeli drug maker said.

     

    The company said its exploratory clinical trial of the oral insulin capsule ORMD-0801 was successful. The company is developing the capsule as a treatment for patients with uncontrolled Type 1 diabetes. The company also is developing the oral insulin as a treatment for Type 2 diabetes.

     

     

  • Safeway offering Fluzone High-Dose to seniors

    PLEASANTON, Calif. Safeway on Tuesday announced that all Safeway pharmacies in the United States now have a new high-dose flu vaccine called Fluzone High-Dose, which has been approved by the Food and Drug Administration for use in people 65 years of age and older.

     

  • Q&A: Life after the NCPA

    After a distinguished, eight-and-a-half-year tenure as chief of the National Community Pharmacists Association, Bruce Roberts, independent pharmacy’s toughest champion, retired June 25 as NCPA’s EVP and CEO. He now is president and CEO of Benecard Services, a small pharmacy benefit manager and prescription benefit facilitator firm founded by pharmacist Richard Ullman. Roberts, a longtime former independent pharmacy owner in Leesburg, Va., brought energy and passion to his role and helped spur a resurgence, both for the organization and independent pharmacy.

  • FDA clarifies position on low blood pressure drug

    PHILADELPHIA The Food and Drug Administration did not completely withdraw from the market a drug used to treat a dangerous low blood pressure condition, but merely proposed to do so as a “step in the regulatory process,” according to a document posted on the agency’s website Monday.

    The agency said its proposal last month to withdraw approval for Shire’s drug ProAmatine (midodrine) did not represent the actual withdrawal of the drug from the market, while calling for more data on the drug to verify its clinical benefit.

     

  • FDA accepts approval application for Fluzone Intradermal

    SWIFTWATER, Pa. The Food and Drug Administration has accepted a regulatory approval application for a flu vaccine administered in the skin.

     

    Sanofi Pasteur, the vaccines arm of French drug maker Sanofi-Aventis, announced Monday that the FDA had accepted its application for Fluzone Intradermal (influenza virus vaccine). The company expects the FDA to take action on the vaccine in the first half of next year.

     

     

  • Generic versions of Copaxone hit roadblock

    NEW YORK Efforts by two generic drug makers to market a generic version of a drug for multiple sclerosis hit an obstacle this week in a U.S. District Court.

     

    The U.S. District Court for the Southern District of New York denied a motion for summary judgment filed by Sandoz and Momenta Pharmaceuticals that patents covering Teva Pharmaceutical Industries’ drug Copaxone (glatiramer acetate) are invalid due to indefiniteness.

     

     

  • PhRMA: Drug, vaccine development for infectious diseases grows

    BOSTON Close to 400 drugs and vaccines are in development for fighting infectious diseases, according to one of the pharmaceutical industry’s largest lobbying groups.

     

    The Pharmaceutical Research and Manufacturers of America announced Friday that drug makers have 395 new medicines and vaccines in clinical development or under review by the Food and Drug Administration. These include five vaccines and six drugs for malaria, as well as agents for infections like cholera, methicillin-resistant Staphylococcus aureus and the Ebola virus.

     

  • Active phone prompts spur Rx adherence rates among consumers, CVS reveals

    WOONSOCKET, R.I. Consumers are much more likely to adhere to their prescription medication therapy if given “a clear and active choice” in recorded telephone prompts from their pharmacy, new research into patient compliance from CVS Caremark demonstrated.

     

X
This ad will auto-close in 10 seconds